What it sells
The agentic drug company. We simulate human biology.
Business model breakdown
Buyer: who owns the budget?
UnverifiedHeads of R&D / translational science at pharma and biotech.
Trigger: what makes them buy now?
Need to prioritize compounds before expensive physical assays and kill unsafe programs before clinic.
Workflow: what inputs become what output?
Virtual compound screening, cross-species transfer to predict human toxicity, and linking preclinical interventions to patient evidence for responder signatures and trial design; model fine-tuned on customer proprietary assays.
Economics: what it saves and how it charges
Likely enterprise platform licence or partnership deployed on-prem or in customer VPC; no prices shown. Validation claim: 4,266 compounds screened, 23 prioritized, 3 validated hits in ex-vivo tumor tissue.
Distribution: how it reaches customers
UnverifiedPartnership-led ('Partner with us'); enterprise direct deployment.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.